|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2007-3-19
|
|
pubmed:abstractText |
Expression of Bcl-2 protein is associated with chemotherapy resistance and decreased survival in chronic lymphocytic leukemia (CLL). We evaluated whether oblimersen would improve response to chemotherapy in patients with relapsed or refractory CLL.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:BociekR GregoryRG,
pubmed-author:BoydThomas ETE,
pubmed-author:Chanan-KhanAsher AAA,
pubmed-author:KozinerBenjaminB,
pubmed-author:LarrattLoree MLM,
pubmed-author:MooreJoseph OJO,
pubmed-author:O'BrienSusanS,
pubmed-author:PavleticSteveS,
pubmed-author:RaiKanti RKR,
pubmed-author:SeymourJohn FJF,
pubmed-author:SkotnickiAleksanderA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1114-20
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17296974-Adult,
pubmed-meshheading:17296974-Aged,
pubmed-meshheading:17296974-Aged, 80 and over,
pubmed-meshheading:17296974-Antineoplastic Agents,
pubmed-meshheading:17296974-Antineoplastic Agents, Alkylating,
pubmed-meshheading:17296974-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17296974-Cyclophosphamide,
pubmed-meshheading:17296974-Drug Administration Schedule,
pubmed-meshheading:17296974-Female,
pubmed-meshheading:17296974-Follow-Up Studies,
pubmed-meshheading:17296974-Genes, bcl-2,
pubmed-meshheading:17296974-Humans,
pubmed-meshheading:17296974-Kaplan-Meier Estimate,
pubmed-meshheading:17296974-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:17296974-Male,
pubmed-meshheading:17296974-Middle Aged,
pubmed-meshheading:17296974-Oligonucleotides, Antisense,
pubmed-meshheading:17296974-Proportional Hazards Models,
pubmed-meshheading:17296974-Recurrence,
pubmed-meshheading:17296974-Thionucleotides,
pubmed-meshheading:17296974-Time Factors,
pubmed-meshheading:17296974-Treatment Failure,
pubmed-meshheading:17296974-Treatment Outcome,
pubmed-meshheading:17296974-Vidarabine
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
|
|
pubmed:affiliation |
Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030;, USA. sobrien@mdanderson.org
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
